{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:12:08Z","timestamp":1787019128577,"version":"build-2736575974"},"reference-count":44,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Recent FDA approval of difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase for the prevention of neuroblastoma in children, has renewed interest in this medication for the prevention of other cancers including keratinocyte carcinomas (KCs). It has been investigated for cancer chemoprevention, including neoplasms of the colon, breast, and prostate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We assessed the current body of literature that determines DFMO efficacy and safety in non-melanoma skin cancer prevention. A systematic search of PubMed Central, and Web of Sciences was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In this analysis, 12 studies were included evaluating 1618 patients. Most patients were Caucasian 90% (1452\/1618) with a mean age of 61 years, and 73% (1214\/1618) had previously been diagnosed with KC. For oral DFMO, reduction in KC was significant in 24% (291\/1214) of patients. Nonsignificant reduction was observed in 17% (207\/1214) of patients. The remaining studies, representing 59% (716\/1214) of patients explored DFMO\u2019s pharmacological\/biological effects without elucidating its direct impact on KC. Topical DFMO shows modest efficacy in reducing the number of actinic keratosis (AK), as indicated in 4 studies representing 38.12% (154\/404) of patients. For patients taking the oral eflornithine, the most frequently reported adverse events included reversible ototoxicity (11% of patients) gastrointestinal disturbances (10.39%). For the topical DFMO transient local cutaneous eruptions were common impacting 28.76% (111\/386) of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Current evidence highlights the lack of conclusive data supporting the efficacy of oral DFMO, making it difficult to recommend its use. Conversely, topical DFMO demonstrates more promising outcomes in preventing AKs, presenting a potentially useful alternative in select patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/12034754241302818","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T06:54:27Z","timestamp":1732949667000},"page":"143-149","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating Difluoromethylornithine Safety and Efficacy for Non-Melanoma Skin Cancer Chemoprevention: A Systematic Review"],"prefix":"10.1177","volume":"29","author":[{"given":"Kaouthar","family":"Koulmi","sequence":"first","affiliation":[{"name":"Department of Medicine, McGill University, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-1476","authenticated-orcid":false,"given":"Leila","family":"Cattelan","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-4675","authenticated-orcid":false,"given":"Ivan V.","family":"Litvinov","sequence":"additional","affiliation":[{"name":"Cancer Research Program, McGill University Health Centre Research Institute, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-020-00563-6"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-019-01454-z"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10830.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005082"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419852048"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153753"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194726"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-23-0545"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-0652"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.4781"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000269707.06060.dc"},{"issue":"3","key":"e_1_3_2_13_2","first-page":"233","article-title":"Neoplastic complications of transplantation","volume":"8","author":"Penn I","year":"1993","unstructured":"Penn I. Neoplastic complications of transplantation. Semin Respir Infect. 1993;8(3):233-239.","journal-title":"Semin Respir Infect"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419867616"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/12034754241274368"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020171"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012622"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054989"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22348"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1353377"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-002-0766-5"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001182"},{"issue":"10","key":"e_1_3_2_23_2","first-page":"1","article-title":"Treatments for unwanted facial hair","volume":"10","author":"Shapiro J","year":"2005","unstructured":"Shapiro J, Lui H. Treatments for unwanted facial hair. Skin Therapy Lett. 2005;10(10):1-4.","journal-title":"Skin Therapy Lett"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01545-9"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.1.57"},{"issue":"10","key":"e_1_3_2_26_2","first-page":"3105","article-title":"A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers","volume":"8","author":"Fabian CJ","year":"2002","unstructured":"Fabian CJ, Kimler BF, Brady DA, et al. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res. 2002;8(10):3105-3117.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"e_1_3_2_27_2","first-page":"759","article-title":"Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy","volume":"48","author":"Pegg AE","year":"1988","unstructured":"Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. 1988;48(4):759-774.","journal-title":"Cancer Res"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"issue":"3","key":"e_1_3_2_29_2","first-page":"513","article-title":"Incidence of skin cancer in 5356 patients following organ transplantation","volume":"143","author":"Lindelof B","year":"2000","unstructured":"Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143(3):513-519.","journal-title":"Br J Dermatol"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.12.1524"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.37680"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02875"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.16.1212"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.9.732"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.58347\/tml.2024.1702f"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32659-w"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2007.45862"},{"issue":"3","key":"e_1_3_2_38_2","first-page":"243","article-title":"Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans","volume":"2","author":"Creaven PJ","year":"1993","unstructured":"Creaven PJ, Pendyala L, Petrelli NJ. Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans. Cancer Epidemiol Biomarkers Prev. 1993;2(3):243-247.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.1250.13.7"},{"issue":"7","key":"e_1_3_2_40_2","first-page":"843","article-title":"Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer","volume":"70","author":"Abeloff MD","year":"1986","unstructured":"Abeloff MD, Rosen ST, Luk GD, Baylin SB, Zeltzman M, Sjoerdsma A. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer. Cancer Treat Rep. 1986;70(7):843-845.","journal-title":"Cancer Treat Rep"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-09-0096"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.30231"},{"issue":"5","key":"e_1_3_2_43_2","first-page":"371","article-title":"Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials","volume":"5","author":"Loprinzi CL","year":"1996","unstructured":"Loprinzi CL, Messing EM, O\u2019Fallon JR, et al. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol Biomarkers Prev. 1996;5(5):371-374.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-15-0232"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-1-62"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754241302818","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/12034754241302818","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754241302818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:51:19Z","timestamp":1777391479000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/12034754241302818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1177\/12034754241302818"],"URL":"https:\/\/doi.org\/10.1177\/12034754241302818","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]}}}